Thomas Babcock

Summary

Affiliation: Shire BioChem Inc

Publications

  1. pmc Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder
    Greg W Mattingly
    St Charles Psychiatric Associates Midwest Research, 4801 Weldon Spring Pkwy, Suite 300, St Charles, MO, USA
    BMC Psychiatry 13:39. 2013
  2. pmc Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study
    Thomas Babcock
    Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA
    BMC Pharmacol Toxicol 13:18. 2012
  3. pmc Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis
    Rakesh Jain
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, Texas, and R D Clinical Research, Inc, Lake Jackson, Texas, USA
    Child Adolesc Psychiatry Ment Health 5:35. 2011
  4. doi request reprint Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective
    Thomas Babcock
    Shire Pharmaceuticals, 725 Chesterbrook Road, Wayne, PA 19087 5637, USA
    Postgrad Med 121:73-82. 2009
  5. doi request reprint Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity
    Lawrence Ginsberg
    Red Oak Psychiatry Associates, PA, Houston, TX 77090, USA
    Curr Med Res Opin 27:1097-107. 2011

Collaborators

  • Lenard A Adler
  • Bryan Dirks
  • Ben Adeyi
  • Brian Scheckner
  • Robert Lasser
  • Greg W Mattingly
  • Rakesh Jain
  • Lawrence Ginsberg
  • Richard H Weisler
  • Joel Young
  • David W Goodman
  • Alain Katic
  • Teodor Burtea

Detail Information

Publications5

  1. pmc Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder
    Greg W Mattingly
    St Charles Psychiatric Associates Midwest Research, 4801 Weldon Spring Pkwy, Suite 300, St Charles, MO, USA
    BMC Psychiatry 13:39. 2013
    ..This study examined clinical response and symptomatic remission in analyses of 2 studies of lisdexamfetamine dimesylate (LDX) in adults with ADHD...
  2. pmc Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study
    Thomas Babcock
    Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA, 19087, USA
    BMC Pharmacol Toxicol 13:18. 2012
    ..Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, laboratory findings, and electrocardiogram...
  3. pmc Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis
    Rakesh Jain
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, Texas, and R D Clinical Research, Inc, Lake Jackson, Texas, USA
    Child Adolesc Psychiatry Ment Health 5:35. 2011
    ..abstract:..
  4. doi request reprint Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective
    Thomas Babcock
    Shire Pharmaceuticals, 725 Chesterbrook Road, Wayne, PA 19087 5637, USA
    Postgrad Med 121:73-82. 2009
    ..Although rates of psychiatric comorbidity are high in adults with ADHD, available data suggest that the benefits of pharmacotherapy for ADHD are not compromised by the presence of psychiatric comorbidity...
  5. doi request reprint Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity
    Lawrence Ginsberg
    Red Oak Psychiatry Associates, PA, Houston, TX 77090, USA
    Curr Med Res Opin 27:1097-107. 2011
    ..To examine the impact of baseline severity on lisdexamfetamine dimesylate (LDX) efficacy in a long-term study of adults with attention-deficit/hyperactivity disorder (ADHD)...